Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Regulatory Pipeline Includes DTC, Inspection Requirement Updates

Executive Summary

Additionally, potential regulation to require clinical study sponsors to promptly report suspected data falsification seems to have found new life after being listed as inactive in July update of the Unified Agenda.

Advertisement

Related Content

Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
Generic Labeling Rule Dies In Latest Reg Agenda, But Electronic Labeling Is Reborn
Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Generic Labeling Rule Defies Predictions, Remains In FDA's Long-Term Pipeline

Topics

Advertisement
UsernamePublicRestriction

Register

PS122186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel